Related Experiment Videos
Combination therapy with an antioxidant and a corticosteroid prevents autoimmune diabetes in NOD mice
A Rabinovitch1, W L Suarez, R F Power
1Department of Medicine, University of Alberta, Edmonton, Canada.
Abstract:
Oxygen free radicals have been implicated as mediators of pancreatic islet beta cell damage in autoimmune, insulin-dependent diabetes mellitus (IDDM). In this study, we show that the antioxidant, probucol, produced only a small decrease in diabetes incidence in nonobese diabetic (NOD) mice, an animal model for human IDDM. However, combination of probucol with the antiinflammatory corticosteroid, deflazacort, produced an early synergistic effect, delaying diabetes onset by 3 weeks, and a later additive effect, decreasing diabetes incidence from 68% (17 of 25 mice) to 23% (6 of 26 mice, p < 0.005). Protection against diabetes by the combination of probucol and deflazacort was associated with a significant decrease in pancreatic islet infiltration by macrophages/lymphocytes (insulitis) and prevention of islet beta cell loss.
Insights
This study investigated treatments for autoimmune diabetes in nonobese diabetic mice. Combining probucol and deflazacort significantly reduced diabetes incidence by preventing pancreatic islet damage.
Area of Science:
- Immunology
- Endocrinology
- Pharmacology
Background:
- Autoimmune diabetes involves pancreatic islet beta cell damage mediated by oxygen free radicals.
- Nonobese diabetic (NOD) mice serve as a model for human insulin-dependent diabetes mellitus (IDDM).
Purpose of the Study:
- To evaluate the efficacy of the antioxidant probucol and the anti-inflammatory corticosteroid deflazacort in preventing autoimmune diabetes in NOD mice.
- To determine if a combination therapy of probucol and deflazacort offers synergistic or additive protective effects against diabetes onset and progression.
Main Methods:
- NOD mice were treated with probucol alone, deflazacort alone, or a combination of both agents.
- Diabetes incidence and onset were monitored over time.
- Histological analysis of pancreatic islets was performed to assess insulitis (immune cell infiltration) and beta cell loss.
Main Results:
- Probucol alone showed minimal reduction in diabetes incidence.
- The combination of probucol and deflazacort demonstrated a synergistic effect, delaying diabetes onset by 3 weeks.
- Combined therapy significantly decreased diabetes incidence from 68% to 23% (p < 0.005).
- Protection was associated with reduced insulitis and preserved islet beta cells.
Conclusions:
- Combined administration of probucol and deflazacort is an effective strategy for preventing autoimmune diabetes in NOD mice.
- The combination therapy acts through reducing insulitis and preventing beta cell destruction.
- This approach holds potential for therapeutic interventions in human autoimmune diabetes.